Want to join the conversation?
John Kernan of Cowen asks about the margin recovery opportunity in 4Q16. COO & Interim CFO Andre Hawaux replied that $DKS expects to see some improvement in gross margin in 3Q16, as well as the full year 2016, but the company has not guided specifically to 4Q16 yet.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.